Dr. Andrew Neukirch plans to return to clinical practice in the near future.
Dr. Neukirch is a distinguished optometrist and healthcare leader dedicated to advancing the business and clinical practice of modern eye care. A graduate of Indiana University with a Doctorate of Optometry, he has established himself as a leading authority in myopia management and practice development.
Dr. Neukirch is best known for revitalizing the longest-standing private optometric practice on Chicago’s North Shore. Under his ownership, he drove operational growth of over 400% in just ten years, transforming the clinic into the region's largest single-location private practice. His tenure was defined by a commitment to clinical excellence, particularly in myopia management, ocular disease, and specialty contact lens care. This sustained success and operational prestige led to the practice’s successful acquisition by a major private equity group in 2021.
Widely recognized for his contributions to the field, Dr. Neukirch has been named the Illinois Optometrist of the Year and a Vision Monday Optometric Business Innovator. He also held the distinction of being the top prescribing optometrist for MiSight lenses in the United States for multiple consecutive years, underscoring his dedication to innovative treatment adoption.
Currently, Dr. Neukirch serves as a consultant and speaker for leading industry partners while observing a professional sabbatical from direct patient care.
Based in Glenview, IL, Dr. Neukirch offers specialized consulting services tailored to industry leaders and private practices alike.
Turn Clinical Excellence into a Practice Builder.
Bullimore MA, Saunders KJ, Baraas RC, et al. IMI–Interventions for Controlling Myopia Onset and Progression 2025. Invest Ophthalmol Vis Sci. 2025;66(12):39.
Chamberlain P, Lazon de la Jara P, Arumugam B, Bullimore MA. Axial Length Targets for Myopia Control. Ophthalmic Physiol Opt. 2021;41(3):523-531.
COMET Group. Myopia Stabilization and Associated Factors among Participants in the Correction of Myopia Evaluation Trial (COMET). Invest Ophthalmol Vis Sci. 2013;54(13):7871-7884.
Flitcroft I, Bullimore MA, Gifford KL, et al. Myopia Correction, Myopia Control and Myopia Management: Definitions and Recommended Usage. Invest Ophthalmol Vis Sci. 2025;66(6):41.
Haarman AEG, Enthoven CA, Tideman JWL, et al. The Complications of Myopia: A Review and Meta-Analysis. Invest Ophthalmol Vis Sci. 2020;61(4):49.
Hu Y, Ding X, Guo X, et al. Association of Age at Myopia Onset with Risk of High Myopia in Adulthood in a 12-Year Follow-up of a Chinese Cohort. JAMA Ophthalmol. 2020;138(11):1129-1134.
Li X, Huang Y, Liu C, et al. Myopia Control Efficacy of Spectacle Lenses with Highly Aspherical Lenslets: Results of a 5-Year Follow-up Study. Eye Vis (Lond). 2025;12:10.
Modjtahedi BS, Abbott RL, Fong DS, et al. Reducing the Global Burden of Myopia by Delaying the Onset of Myopia and Reducing Myopic Progression in Children. Ophthalmology. 2021;128(6):816-826.
National Academies of Sciences, Engineering, and Medicine. Myopia: Causes, Prevention, and Treatment of an Increasingly Common Disease. Washington, DC: The National Academies Press; 2024.
Tideman JWL, Snabel MC, Tedja MS, et al. Association of Axial Length with Risk of Uncorrectable Visual Impairment for Europeans with Myopia. JAMA Ophthalmol. 2016;134(12):1355-1363.
Ueda E, Yasuda M, Fujiwara K, et al. Trends in the Prevalence of Myopia and Myopic Maculopathy in a Japanese Population: The Hisayama Study. Invest Ophthalmol Vis Sci. 2019;60(8):2781-2786.
Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial. Ophthalmology. 2019;126(1):113-124.
Yam JC, Zhang XJ, Zhang Y, et al. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA. 2023;329(6):472-481.
Zadnik K, Sinnott LT, Cotter SA, et al. Prediction of Juvenile-Onset Myopia. JAMA Ophthalmol. 2015;133(6):683-689.
Stay updated on Dr. Neukirch's news and upcoming events! Sign up to receive the newsletter.
